Multimodal approach: The patient will undergo MRI, PET/can and biological samples
Study summary
The goal of the study lies in offering a multimodal analysis of the post-therapeutic response based on both quantitative parameters and radiomics (CT, MRI, and PET imaging), and on tumor biology, in particular the hypersensitive detection of tumor DNA.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patient with squamous cell carcinoma of the oropharynx (cT2-cT4) or squamous cell carcinoma of the oral cavity (cT2-cT4)
* With lymph node involvement (cN1, cN2, or cN3) (confirmation of lymph node involvement after review of imaging in CCP and without histological confirmation required)
* Eligible for curative treatment with cisplatin-based chemoradiotherapy alone (100 mg/m2 every 3 weeks or 40 mg/m2 weekly)
* Regardless of p16 status
* Affiliated with or covered by a social security system
Exclusion Criteria:
* Head and neck squamous cell carcinomas in other locations (salivary gland, larynx, hypopharynx, cavum, sinuses)
* Primary squamous cell carcinoma of the lymph nodes
* History of radiotherapy to the head and neck region
* Radiochemotherapy not based on the use of cisplatin
* Pregnant or breastfeeding women
* History of invasive cancer in the last 3 years (except for Breslow melanoma less than 1 mm)
* Contraindication to MRI, CT, or PET/CT
* Allergy or contraindication to iodine, gadolinium, or 18F-FDG
* Uncontrolled diabetes (fasting blood glucose greater than 12 mmol/l)
* Patients unable to understand the study for any reason or to comply with the trial requirements (language, psychological, geographical issues, etc.)
* Patients under guardianship or conservatorship
* Patients deprived of their liberty by judicial or administrative decision
* Patients undergoing psychiatric care that renders them incapable of giving their consent
* Patients admitted to a health or social care facility for purposes other than research
Primary outcome measure(s)
Performance of multimodal approach to predict response to chemoradiation — 12 months after treatment Estimation of the area under the curve associated with the overall performance of the combined score established by the multimodal approach (PET/CT, MRI, CT, circulating tumor DNA, lymph node tumor DNA) in the post-CRT assessment of the status of a locoregional response within 12 months after chemoradiation.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
